Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Cellectis SA ( (CLLS) ).
Cellectis S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission on May 11, 2026, furnishing its unaudited interim condensed consolidated financial statements for the three-month period ended March 31, 2026. The interim report, prepared under IAS 34 and presented in U.S. dollars, is incorporated by reference into several of the company’s existing U.S. shelf and employee share plan registration statements, formally updating investors’ access to its latest financial and risk disclosures.
The filing, signed by Chief Executive Officer André Choulika, reinforces Cellectis’s compliance with U.S. reporting requirements for foreign private issuers and ensures its capital-raising frameworks remain current. By updating the financial statements and related management discussion, the company provides stakeholders with fresh visibility into its balance sheet, risk factors and market exposures at the end of the first quarter of 2026, which may influence investor perception and future financing activity.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a France-based biotechnology company specializing in gene-editing technologies, notably its TALEN platform, to develop targeted cell and gene therapies. The group operates globally in the life sciences sector, focusing on oncology and other therapeutic areas through proprietary programs and collaborations, and reports its consolidated financials in U.S. dollars.
Average Trading Volume: 39,950
Technical Sentiment Signal: Buy
Current Market Cap: $272.1M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.